| 000 | 01821 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250516141701.0 | ||
| 264 | 0 | _c20130710 | |
| 008 | 201307s 0 0 eng d | ||
| 022 | _a2325-8179 | ||
| 024 | 7 |
_a10.3928/23258160-20130313-04 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWykoff, Charles C | |
| 245 | 0 | 0 |
_aSAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. _h[electronic resource] |
| 260 |
_bOphthalmic surgery, lasers & imaging retina _c |
||
| 300 |
_a121-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Historical Article; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFluorescein Angiography |
| 650 | 0 | 4 | _aHistory, 18th Century |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIntravitreal Injections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRanibizumab |
| 650 | 0 | 4 | _aRefraction, Ocular |
| 650 | 0 | 4 | _aTomography, Optical Coherence |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVisual Acuity _xphysiology |
| 650 | 0 | 4 |
_aWet Macular Degeneration _xdiagnosis |
| 700 | 1 | _aBrown, David M | |
| 700 | 1 | _aChen, Eric | |
| 700 | 1 | _aMajor, James C | |
| 700 | 1 | _aCroft, Daniel E | |
| 700 | 1 | _aMariani, Angeline | |
| 700 | 1 | _aWong, Tien P | |
| 773 | 0 |
_tOphthalmic surgery, lasers & imaging retina _gvol. 44 _gno. 2 _gp. 121-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3928/23258160-20130313-04 _zAvailable from publisher's website |
| 999 |
_c22596746 _d22596746 |
||